Harmony Biosciences Holdings (HRMY) Cash from Operations (2019 - 2026)

Harmony Biosciences Holdings (HRMY) has 8 years of Cash from Operations data on file, last reported at 27760000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations fell 18.32% year-over-year to 27760000.0; the trailing twelve-month figure through Mar 2026 stood at 341972000.0 (up 53.58% YoY), and the FY2025 full-year result was 348199000.0, up 58.4% from the prior year.
• Cash from Operations declined to 27760000.0 in Q1 2026, from 126151000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 126151000.0 in Q4 2025 to a low of 26678000.0 in Q4 2022.
• A 5-year average of 56449000.0 and a median of 42617000.0 in 2024 frame the typical range for Cash from Operations.
• Across the five-year window, Cash from Operations retreated 28.92% in 2022 and soared 187.37% in 2023, its largest moves.
• Tracing HRMY's Cash from Operations over 5 years: stood at 26678000.0 in 2022, then soared by 187.37% to 76665000.0 in 2023, then declined by 1.44% to 75562000.0 in 2024, then jumped by 66.95% to 126151000.0 in 2025, then tumbled by 77.99% to 27760000.0 in 2026.
• Business Quant data shows HRMY's Cash from Operations at 27760000.0 in Q1 2026, 126151000.0 in Q4 2025, and 108734000.0 in Q3 2025.